Hunan Zhongnan Pharmaceutical Co., Ltd.

A randomized, open, two-treatment, two-period crossover design was used to evaluate the oral bioequivalence of clozapine tablets (25 mg/tablet) produced by Hunan Zhongnan Pharmaceutical Co., Ltd. and clozapine tablets (25 mg/tablet, trade name: Clozaril®) certified by HERITAGE LIFE SCIENCES BARBADOS INC in Chinese schizophrenia subjects, to provide evidence for the consistency of clinical efficacy between clozapine tablets produced by Hunan Zhongnan Pharmaceutical Co., Ltd. and clozapine tablets certified by HERITAGE LIFE SCIENCES BARBADOS INC. The safety of the test preparation clozapine tablets and the reference preparation clozapine tablets in subjects was observed.

Primary objective: To compare the differences in the extent and rate of absorption of Benhexyphenidyl Hydrochloride Tablets (Specification: 2 mg/tablet) provided by Hunan Zhongnan Pharmaceutical Co., Ltd. and Benhexyphenidyl Hydrochloride Tablets (Specification: 2 mg/tablet) produced by Watson Pharma Private Limited in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of the test preparation and the reference preparation Benhexyphenidyl Hydrochloride Tablets (2 mg/tablet) in healthy subjects under fasting and postprandial administration conditions.